Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 0.3%
Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 0.3%
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Rating)'s share price rose 0.3% on Tuesday . The company traded as high as $12.47 and last traded at $11.58. Approximately 64,816 shares were traded during mid-day trading, an increase of 348% from the average daily volume of 14,469 shares. The stock had previously closed at $11.55.
Wall Street Analyst Weigh In
ACRV has been the subject of a number of analyst reports. Piper Sandler initiated coverage on shares of Acrivon Therapeutics in a research report on Sunday, December 11th. They issued an "overweight" rating and a $25.00 price objective for the company. Cowen initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set an "outperform" rating for the company. Jefferies Financial Group initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set a "buy" rating and a $17.00 price target for the company. Finally, Cowen initiated coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They set an "outperform" rating for the company.
Get Acrivon Therapeutics alerts:Acrivon Therapeutics Trading Up 0.3 %
Insider Activity at Acrivon Therapeutics
In other Acrivon Therapeutics news, major shareholder Ltd Chione acquired 400,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The stock was bought at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the purchase, the insider now owns 3,856,597 shares in the company, valued at $48,207,462.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Acrivon Therapeutics news, major shareholder Ltd Chione acquired 400,000 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The stock was bought at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the purchase, the insider now owns 3,856,597 shares in the company, valued at $48,207,462.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. acquired 3,389,500 shares of the company's stock in a transaction that occurred on Thursday, November 17th. The shares were acquired at an average cost of $12.50 per share, with a total value of $42,368,750.00. Following the purchase, the director now owns 4,384,206 shares in the company, valued at approximately $54,802,575. The disclosure for this purchase can be found here.
About Acrivon Therapeutics
(Get Rating)Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Read More
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Mobileye Expects $17.5 Billion Future For Its Driver Assist Tech
- Is Salesforce's New Rally The Beginning Of A Big Uptrend?
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
阿裡馮治療公司(納斯達克代碼:ACRV-GET)股價週二上漲0.3%,盤中一度漲至12.47美元,最新報11.58美元。午盤成交量約為64,816股,較14,469股的日均成交量增長348%。該股此前收盤報11.55美元。
華爾街分析師也加入進來
ACRV一直是許多分析師報告的主題。派珀·桑德勒在12月11日(星期日)的一份研究報告中對Acrivon Treeutics的股票進行了報道。他們對該公司的評級為“增持”,目標價為25美元。考恩在12月12日星期一的一份研究報告中開始了對Acrivon治療公司股票的報道。他們為該公司設定了“跑贏大盤”的評級。傑富瑞金融集團在12月12日星期一的一份研究報告中啟動了對Acrivon治療公司股票的報道。他們為該公司設定了“買入”評級和17.00美元的目標價。最後,考恩在12月12日星期一的一份研究報告中開始了對Acrivon治療公司股票的報道。他們為該公司設定了“跑贏大盤”的評級。
到達阿克瑞豐治療公司警報:Acrivon治療公司股價上漲0.3%
Acrivon Treeutics的內部活動
在Acrivon治療公司的其他消息中,大股東有限公司Chione在11月17日星期四的一筆交易中購買了40萬股該公司的股票。該股以每股12.50美元的平均價購入,總價值為5,000,000.00美元。收購完成後,這位內部人士現在擁有該公司3856,597股票,價值48,207,462.50美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過這個環節。在Acrivon治療公司的其他消息中,大股東有限公司Chione在11月17日星期四的一筆交易中購買了40萬股該公司的股票。該股以每股12.50美元的平均價購入,總價值為5,000,000.00美元。收購完成後,這位內部人士現在擁有該公司3856,597股票,價值48,207,462.50美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過這個環節。此外,董事在11月17日(星期四)的一次交易中收購了3389,500股該公司的股票。這些股票是以每股12.50美元的平均成本收購的,總價值為42,368,750.00美元。收購完成後,董事現在擁有該公司4384,206股,價值約54,802,575美元。關於這次購買的披露可以找到這裡。
關於Acrivon治療公司
(獲取評級)Acrivon治療公司是一家臨床階段的生物製藥公司,該公司致力於開發精確腫瘤學藥物,通過利用其基於蛋白質組學的患者回應者識別平臺Acrivon Predictive Precision Protetics(AP3),將其與預測其腫瘤對特定藥物敏感的患者相匹配。
閱讀更多內容
- 免費獲取StockNews.com關於Acrivon治療公司(ACRV)的研究報告
- Mobileye預計其駕駛員輔助技術未來價值175億美元
- Salesforce的新一輪漲勢是大漲趨勢的開始嗎?
- 洛克希德·馬丁公司第一季度能否再創歷史新高?
- 馬拉松數位控股公司:穩紮穩打贏得比賽
- WD-40公司已經準備好反彈了,但它會嗎?
獲得Acrivon治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acrivon Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧